Standout Papers

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-C... 2022 2026 2023 2024210
  1. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study (2022)
    Melissa L. Johnson, Byoung Chul Cho et al. Journal of Clinical Oncology

Immediate Impact

12 by Nobel laureates 1 from Science/Nature 51 standout
Sub-graph 1 of 17

Citing Papers

Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy
2025 Standout
Traditional Chinese medicine in lung cancer treatment
2025 Standout
3 intermediate papers

Works of Grygorii Ursol being referenced

Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
2022 Standout

Author Peers

Author Last Decade Papers Cites
Grygorii Ursol 209 131 50 6 238
Farah Louise Lim 225 146 52 7 257
Hai-Yan Tu 235 182 33 5 260
Joanne Riemer 220 130 40 9 254
Ahmed Bilal Khalid 136 98 49 7 221
Yu Yu 134 58 53 6 190
Nicolas Brandone 175 152 35 8 244
Keisuke Onoi 113 71 41 5 155
Silvana Acquafredda 151 90 42 8 223
Amita Mistry 212 108 55 8 242
W. Victoria Lai 104 86 33 5 166

All Works

Loading papers...

Rankless by CCL
2026